Welcome to LookChem.com Sign In|Join Free
  • or
methyl (3-methyl-4-nitrophenyl)carbamate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

104478-90-2

Post Buying Request

104478-90-2 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

104478-90-2 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 104478-90-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,4,4,7 and 8 respectively; the second part has 2 digits, 9 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 104478-90:
(8*1)+(7*0)+(6*4)+(5*4)+(4*7)+(3*8)+(2*9)+(1*0)=122
122 % 10 = 2
So 104478-90-2 is a valid CAS Registry Number.

104478-90-2Relevant academic research and scientific papers

Synthesis of methyl-1-(tert -butoxycarbonylamino)-2- vinylcyclopropanecarboxylate via a hofmann rearrangement utilizing trichloroisocyanuric acid as an oxidant

Crane, Zackary D.,Nichols, Paul J.,Sammakia, Tarek,Stengel, Peter J.

, p. 277 - 280 (2011)

A trichloroisocyanuric acid (TCCA) mediated Hofmann rearrangement was utilized to synthesize methyl-1-(tert-butoxycarbonylamino)-2- vinylcyclopropanecarboxylate. A variety of functional groups are tolerated in this reaction including vinyl, cyclopropyl, pyridyl, aryl, benzyl, and nitro groups.

COMPOUNDS FOR INHIBITING TNIK AND MEDICAL USES THEREOF

-

Paragraph 604-607, (2019/08/29)

The present disclosure provides the compound having inhibitory property against TNIK having a specific chemical structure or its pharmaceutically acceptable salt. The present disclosure also provides a composition comprising the compound or its pharmaceutically acceptable salt. The present disclosure also provides a medical use of the compound, its salt or the composition comprising the compound or its pharmaceutically acceptable salt for treating or preventing cancer. The present disclosure also provides a method of treatment or prevention of cancer comprising administering the compound, its salt or the composition comprising the compound or its salt to a subject in need of such treatment or prevention.

Quinone Imine Route to Benzimidazol-2-ylcarbamates. Part 1. Synthesis of Open-chain and Cyclic 5-Acylamino Derivatives.

Rajappa, Srinivasachari,Sreenivasan, Ramaswami,Khalwadekar, Asha

, p. 1657 - 1675 (2007/10/02)

The synthesis of the N',N''-bismethoxycarbonyl-N-(4-acylaminophenyl)guanidines (4) and (7) is described.Oxidation of these with LTA has led to the benzimidazol-2-ylcarbamates. (8), (9) and (10) through a regiospecific cyclisation of quinone imine intermediates.If the acylamino group is part of a ring, the yield of benzimidazoles (15) increases with the size of the lactam ring.The direction of ring closure may be controlled by electronic and steric factors.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 104478-90-2